Rameda

What Rameda does

Rameda (legal name: Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents S.A.E.) is a publicly listed Egyptian pharmaceutical manufacturer founded in 1986 and headquartered in Giza, operating from three fully independent factories with 20 production lines in Cairo's Sixth of October Industrial Zone. The company develops and produces branded generic pharmaceuticals, nutraceuticals, food supplements, and veterinary products, marketing 105 products across 12 therapeutic areas including cardiovascular, diabetes, anti-infectives, CNS, gastrointestinal, ophthalmic, men's health, and antiviral segments. Notable products include Anviziram (Favipiravir for COVID-19), Remdesivir-Rameda, Oliptina (Alogliptin for Type 2 diabetes), Ramelact (Egypt's first lactase enzyme supplement), and a broad antibiotic portfolio anchored by the Kempo and Rame- lines.

The company's revenue model combines direct branded generic sales to pharmacies and healthcare providers in Egypt through a field medical sales force and Training Academy, with export operations to 9 countries managed by a dedicated export team. A secondary B2B toll manufacturing stream serves named clients including Sedico, Amriya, Pharma-Medica, Al-Andalous, Talent-Pharma, Concord, and Pioneer. Rameda is publicly traded on the Egyptian Exchange under ticker RMDA.CA, with LVP Pharma (a subsidiary of healthcare investment firm LimeVest) holding a 31.5% stake following a 2026 share purchase, and a network of over 400 pre-approved licensed doctors supporting patient initiatives. Strategic positioning emphasizes GMP-compliant production quality, multinational-experienced leadership, and portfolio diversification across chronic and acute therapeutic areas, with recent bolt-on acquisitions of cardiometabolic molecules and distribution rights for Physiomer respiratory products.

Name

Rameda

Legal name

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents S.A.E.

Website

https://ramedapharma.com

Company type

Public

Founded year

1986

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Rameda is an Egyptian branded generic pharmaceutical manufacturer operating three factories with 20 production lines, marketing 105 products across 12 therapeutic areas to pharmacies and healthcare providers in Egypt and 9 export countries, with a secondary toll manufacturing business.

Ownership category

akta.pro rank

Headquarters

HQ city

Gîza

HQ country

Egypt

HQ region

Africa

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Rameda develops and produces branded generic pharmaceuticals, nutraceuticals, food supplements and veterinary products sold through pharmacies and healthcare providers in Egypt and export markets.
2. Toll Manufacturing: Rameda provides contract manufacturing services to other pharmaceutical companies including Sedico, Amriya, Pharma-Medica, Al-Andalous, Talent-Pharma, Concord, Pioneer and others.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Rameda develops, manufactures, and markets branded generic pharmaceuticals, nutraceuticals, food supplements, and veterinary products across 12 therapeutic areas. The company operates three fully independent GMP-compliant factories with 20 production lines in Cairo's Sixth of October Industrial Zone, marketing 105+ products domestically in Egypt and exporting to 9 countries. It also provides toll/contract manufacturing services to other pharmaceutical companies.

Product overview

Rameda is a leading Egyptian pharmaceutical company that develops and produces branded generic pharmaceuticals, nutraceuticals, food supplements, and veterinary products. The company operates from three manufacturing facilities in Cairo's Sixth of October Industrial Zone with 20 production lines. Rameda's portfolio includes products across 12 therapeutic areas covering analgesics (Megafen, Megafen N), gastrointestinal products (Lacteol fort, Protofix), anti-infectives (Kempopim, Kempoxone, Rame-Zithro), cardiovascular medications (X-Tension, Tricardia, Normaten), men's health products (Kemporic, Vetoyagra, Joypox), respiratory products (Flu-C, Guaidesca Syrup), antihistamines (Ordesca), ophthalmic products (Lergeblock, Ramedazolamide, Ramedamycin), anti-coagulants (Vaxato), diabetes treatments (Oliptina), CNS/neurology products (Vilaphoria, Nodep, Prismaven), food supplements (Bellavie line, Ramelact, Fortre), and antiviral medications (Molnupiravir-Rameda, Anviziram). As of June 2022, the company marketed 105 products across 9 export countries.

Differentiator

Problem solved

Functional benefit

Products and services

• Ramelact Food supplement in tablet form; Egypt's first lactase enzyme supplement for the treatment of lactose intolerance.
• Oliptina Diabetes medication containing Alogliptin in 30 film-coated tablets for Type 2 diabetes treatment.
• Anviziram Antiviral containing Favipiravir (generic equivalent of Japanese antiviral Avigan) for COVID-19 treatment, priced at EGP 1,260 per 40-tablet pack.
• Remdesivir-Rameda Remdesivir Lyophilized powder for IV Solution Infusion for COVID-19 treatment, priced at EGP 680 per vial.
• Cardiometabolic Portfolio Portfolio of 11 fast-growing cardiometabolic pharmaceutical products acquired to bolster Rameda's chronic disease offerings.
• Megafen Analgesic (pain killer and fever relief) in tablet form, typically dosed as one to two tablets three times daily.
• Megafen N Antipyretic and Analgesic medication dosed at 20 mg/kg/day in equally divided doses 3 to 4 times.
• Lacteol fort GIT Portfolio product containing Lactobacillus LB (12 capsules) for gastrointestinal health.
• Kempopim Broad-spectrum antibiotic (Cefepime) powder for solution I.M./I.V. injection.
• Kemporic Men's health product containing Tadalafil 20mg in 2 film-coated tablets, taken one tablet prior to sexual activity.
• X-Tension Cardiovascular product containing Irbesartan in 28 scored tablets for hypertension treatment.
• Bellavie Immuno Food supplement designed to support immune health.
• Familyvit Pregnancy Prenatal vitamin supplement for pregnancy.
• Molnupiravir-Rameda Antiviral medication containing 200mg Molnupiravir in 30 hard capsules for COVID-19 treatment.
• Fortre Food supplement for iron-deficiency anemia, rich with vitamins and minerals with chocolate flavor (10 sachets).
• Selestoc Food supplement in film-coated tablet form that supports immune system and reduces fatigue.
• Vaxato Anti-coagulant medication available in 2.5mg, 10mg, 15mg, and 20mg dosage forms.
• Tamsunorm

Quantifiable outcome

• 22.95% YoY decline in consolidated profits attributable to parent company in 2025 (EGP 298.464 million vs EGP 387.366 million in 2024)
• +1 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered strategic, minor and major.

• PhysiomerstrategicChannel Partner/ Reseller/ Distributor · 20 December 2022Rameda acquired exclusive rights for the distribution and marketing of Physiomer in Egypt.
• UN Global CompactminorOthers · 20 June 2022Rameda joined the UN Global Compact, the world's largest corporate sustainability initiative.
• IFC (International Finance Corporation)majorStrategic or Co-development Partner · 17 May 2022Rameda Partners with IFC to green its operations in Egypt - corporate sustainability initiative.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• MultiMed Egypt: Egyptian pharmaceutical company producing branded generics. Comparable to Rameda as a fellow Egyptian pharma player in the branded generic space, though with a narrower therapeutic portfolio.

Direct peers

• Eva Pharma: Major Egyptian pharmaceutical company producing branded generics across multiple therapeutic areas. Directly comparable to Rameda in terms of Egyptian market focus, branded generic business model, and broad therapeutic portfolio.
• Amoun Pharmaceutical: Egyptian pharmaceutical manufacturer producing branded generics for human and animal health. Directly comparable to Rameda given overlapping therapeutic areas, Egyptian manufacturing footprint, and similar distribution model.
• AUG Pharma: Egyptian pharmaceutical manufacturer producing branded generics and specialty products. Comparable to Rameda given shared Egyptian market focus and similar branded generic business model, though at smaller scale.
• EIPICO (Egyptian International Pharmaceutical Industries Company): One of the largest Egyptian pharmaceutical manufacturers producing branded generics and APIs. Directly comparable to Rameda as a fellow Egyptian pharma manufacturer with similar product portfolios, distribution channels, and customer base.
• EGYPHAR (Egyptian Pharmaceutical Company): Egyptian pharmaceutical manufacturer focused on branded generics across multiple therapeutic categories. Comparable to Rameda as a fellow Egyptian pharma manufacturer serving similar customers through similar channels.
• Pharco Pharmaceuticals: Largest Egyptian pharmaceutical manufacturer by market share, producing branded generics and biosimilars. Directly comparable to Rameda as a leading Egyptian pharma player with similar product strategy and therapeutic breadth.

Broad incumbents

• Hikma Pharmaceuticals: MENA-focused multinational pharmaceutical company headquartered in Jordan with significant operations in Egypt and the broader region. Comparable to Rameda given regional pharmaceutical focus and branded generic business model, though at significantly larger scale.
• Sanofi Egypt: Multinational pharmaceutical company with established Egyptian operations selling branded pharmaceuticals across multiple therapeutic areas. Comparable to Rameda as a competitor in the Egyptian pharma market, though at much larger scale with different product mix.
• GSK Egypt: Multinational pharmaceutical company's Egyptian subsidiary operating in the same therapeutic categories as Rameda. Comparable as a competitor in the Egyptian pharmaceutical market, though focused on branded innovator products rather than generics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rameda